Scarica l'app Stockscreener
291.77
0.11%
-0.32
Dopo l'orario di chiusura:
293.51
1.74
+0.60%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Amgen Inc Borsa (AMGN) Ultime notizie
Amgen Stock (AMGN) Opinions on Recent Price Dip and Drug Approvals - Quiver Quantitative
Strategic Financial Services Inc. Purchases Shares of 1,217 Amgen Inc. $AMGN - MarketBeat
General American Investors Co. Inc. Sells 5,000 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Purchased by New York Life Investment Management LLC - MarketBeat
Amgen Inc. $AMGN Stock Holdings Lowered by GWN Securities Inc. - MarketBeat
Y Intercept Hong Kong Ltd Buys 7,370 Shares of Amgen Inc. $AMGN - MarketBeat
Bessemer Group Inc. Has $7.16 Million Stake in Amgen Inc. $AMGN - MarketBeat
What dividend safety score for Amgen Inc. stockWeekly Market Report & Long Hold Capital Preservation Tips - newser.com
Is Amgen Poised for Growth After Recent 4% Price Dip? - simplywall.st
Earnings Preview: Amgen (AMGN) Q3 Earnings Expected to Decline - Yahoo Finance
Does Amgen Inc. fit your quant trading modelTrade Exit Summary & Verified Chart Pattern Trade Signals - newser.com
Amgen Inc. stock daily chart insightsJuly 2025 Spike Watch & Accurate Buy Signal Alerts - newser.com
How supply shortages influence Amgen Inc. (AMG) stock2025 Dividend Review & Verified Entry Point Signals - newser.com
Trust Investment Advisors Increases Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Howard Capital Management Inc. Has $5.86 Million Stock Position in Amgen Inc. $AMGN - MarketBeat
Motley Fool Asset Management LLC Acquires 2,924 Shares of Amgen Inc. $AMGN - MarketBeat
Logan Capital Management Inc. Reduces Holdings in Amgen Inc. $AMGN - MarketBeat
Fjarde AP Fonden Fourth Swedish National Pension Fund Has $30.26 Million Position in Amgen Inc. $AMGN - MarketBeat
Will Amgen Inc. (AMG0) stock extend growth storyWeekly Volume Report & Technical Analysis for Trade Confirmation - newser.com
Teacher Retirement System of Texas Sells 8,974 Shares of Amgen Inc. $AMGN - MarketBeat
Transcend Capital Advisors LLC Decreases Stake in Amgen Inc. $AMGN - MarketBeat
Is Amgen Inc. (AMG0) stock undervalued after correctionWatch List & Capital Efficiency Focused Strategies - Fundação Cultural do Pará
Should I buy Amgen Inc. (AMG0) stock before earnings seasonWeekly Trade Review & Daily Chart Pattern Signal Reports - newser.com
What Fibonacci levels say about Amgen Inc. rebound2025 Valuation Update & Fast Exit and Entry Trade Guides - newser.com
Is Amgen Inc. (AMG) stock protected from inflation2025 Support & Resistance & Fast Gaining Stock Reports - newser.com
Why Amgen Inc. (AMG) stock could be top winnerQuarterly Portfolio Summary & Real-Time Chart Breakout Alerts - Fundação Cultural do Pará
Amgen (AMGN) Expected to Announce Earnings on Tuesday - MarketBeat
Using flow based indicators on Amgen Inc.2025 Support & Resistance & Growth Focused Stock Pick Reports - newser.com
What is the fair value estimate for Amgen Inc. (AMG) stock in 2025Weekly Profit Summary & Fast Gain Stock Tips - newser.com
Will Amgen Inc. (AMG0) stock profit from AI boom2025 Market Sentiment & AI Forecast Swing Trade Picks - newser.com
Will Amgen Inc. (AMG0) stock recover faster than industry2025 Trading Recap & Real-Time Chart Pattern Alerts - newser.com
Will Amgen Inc. (AMG0) stock outperform energy sector in 2025July 2025 Institutional & Weekly Top Performers Watchlists - newser.com
Amgen’s Promising Phase 3 Study on Blinatumomab for Leukemia: What Investors Need to Know - TipRanks
Amgen’s Long-term Study on Dazodalibep: A Potential Breakthrough for Sjögren’s Syndrome - TipRanks
Amgen’s Phase 2a Study on Autoimmune Diseases: A Potential Game-Changer? - TipRanks
Amgen’s Apremilast Study: A Potential Game-Changer for Pediatric Behçet’s Disease - TipRanks
Amgen’s Tarlatamab Study: A Potential Game-Changer in Lung Cancer Treatment - TipRanks
Amgen’s Innovative Study on AMG 193: A Potential Game-Changer in Cancer Treatment - TipRanks
Amgen’s AMG 509 Study: A Potential Game-Changer in Prostate Cancer Treatment - TipRanks
Amgen’s Romiplostim Study: A Potential Game-Changer for Cancer Treatment - TipRanks
Amgen’s Latest Clinical Study Update: A New Hope for Small Cell Lung Cancer? - TipRanks
Amgen’s Apremilast Study: A New Hope for Pediatric Patients - TipRanks
Amgen’s New Prostate Cancer Study: A Potential Game-Changer? - TipRanks
Amgen’s AMG 410 Study: A Potential Game-Changer in KRAS-Altered Tumor Treatment - TipRanks
Amgen’s New Study on Xaluritamig: A Potential Game-Changer in Prostate Cancer Treatment? - TipRanks
Amgen’s Prolia Study: A New Horizon for Male Osteoporosis Treatment in China - TipRanks
Amgen’s Promising Study on Romosozumab for Osteogenesis Imperfecta: A Potential Game-Changer - TipRanks
Amgen’s AMG 355 Study: A Potential Game-Changer in Oncology? - TipRanks
Amgen’s Promising Phase 3 Study on Metastatic Colorectal Cancer - TipRanks
Amgen’s Phase 2 Study on Tarlatamab: A Potential Game-Changer for SCLC Treatment - TipRanks
Amgen’s Pediatric NMOSD Study: A Potential Game-Changer? - TipRanks
Amgen’s Maridebart Cafraglutide: A New Hope for Cardiovascular Health? - TipRanks
Amgen’s Repatha® Study: A Potential Game-Changer in Cardiovascular Care - TipRanks
Amgen’s Latest Clinical Study: A Potential Game-Changer in Lung Cancer Treatment - TipRanks
Amgen’s AMG 193 Study: A Potential Game-Changer in Thoracic Tumor Treatment - TipRanks
Amgen’s Prolia® Study: A New Frontier in Osteoporosis Treatment - TipRanks
Amgen’s Sotorasib Study: A Real-World Evaluation in Chinese NSCLC Patients - TipRanks
Amgen’s Phase 3 Study on Rocatinlimab: A Potential Game-Changer for Prurigo Nodularis - TipRanks
Amgen’s AMG 193 Study: A Potential Game Changer for MTAP-null Solid Tumors - TipRanks
Amgen’s Pediatric Psoriasis Study: A Potential Game-Changer in Dermatology - TipRanks
Amgen’s Latest Study: A New Contender in Lung Cancer Treatment? - TipRanks
Amgen’s AMG 193 Study: A New Hope for Advanced NSCLC Treatment? - TipRanks
Amgen’s New Melanoma Study: A Potential Game-Changer in Cancer Treatment - TipRanks
Amgen’s Xaluritamig Trial: A Potential Game-Changer in Prostate Cancer Treatment - TipRanks
Amgen’s Latest Study on Sotorasib: A Strategic Move in Oncology - TipRanks
0.53%
1.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):